In conclusion, our study offers robust pharmacological evidence that BA, a principal bioactive constituent of PNO, inhibits NSCLC progression by targeting the PI3K/AKT signaling pathway and downregulating ABCB1 expression. The gene discussed is ABCB1; the disease is non-small cell lung carcinoma.